• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]


Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
     
CVM [ CEL-SCI Corp ]
Last Trade 14.25 Date 1/23/2021
Change % 0.43 % Price Change 0.06
Open 14.22 52 Week High 18.0
High 14.36 52 Week Low 6.35
Low 13.7 Type stock
Volume 527891 Average Volume 957937
Prev Close 14.19 Stock Exchange A
Bid 14.08 Ask 14.63
Bid Size 10 Ask Size 9
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.4961 Book Value Yield 0.0348
Buy Back Yield CAPE Ratio
Cash Return -0.03 Cash Flow per Share -0.4156
Cash Flow Yield -0.0292 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0575 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue EV / Total Asset 13.9409
Expected Dividend Growth Rate Free Cash Flow per Share -0.4889
Free Caash Flow Ratio Free Cash Flow Yield -0.0343
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 28.726863 PB Ratio 10 Year Growth 0.157327
PB Ratio 3 Year Growth 6337.533309 Cash Ratio 3 Year Average 2935.4458
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.222127
Price to Cash Ratio 36.539351 Price / EBITDA
Price to Sales Ratio Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg Price to Sales Ratio 5 Year Avg
Sale per Share 0.0 Sales Yield 0.0
Sustainable Growth Rate -2.4358 Tangible Book Value per Share 0.4882
Tangible Book Value per Share 3 year Avg 0.2044 Tangible Book Value per Share 5 year Avg 0.0372
Total Asset per Share 1.0193 Total Yield
Working Capital per Share 0.3378 Working Capital per Share 3 Year Avg 0.202
Working Capital per Share 5 Year Avg 0.0707 Beta 2.598893
Company Profile

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called ?Ligand Epitope Antigen Presentation System? to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.